More Articles

Swiss position statement on the use of biosimilars in IBD Biosimilars/Research | Posted 24/01/2020

Experts from the Swiss Society of Gastroenterology have provided a position statement on the use of biosimilars in inflammatory bowel disease (IBD). The position paper summarizes key regulatory and...

Mundipharma and Samsung Bioepis partner for biosimilars in Hong Kong and Taiwan Pharma News | Posted 24/01/2020

Mundipharma announced on 13 January 2020 that it had entered into a partnership with Korea-based Samsung Bioepis (Samsung and Biogen’s joint venture) to commercialize four biosimilar candidates fro...

Teriparatide biosimilar Terossa approved in South Korea Biosimilars/News | Posted 24/01/2020

South Korea-based Daewon Pharmaceutical has obtained regulatory approval to begin marketing and selling its teriparatide biosimilar in Korea.

Eli Lilly and Novo Nordisk launches lower-priced insulin options Biosimilars/General | Posted 24/01/2020

Originator insulin makers Eli Lilly and Novo Nordisk have both announced the introduction of additional reduced cost insulin options for patients.

FDA sets up centre to improve quality of compounded drugs Generics/General | Posted 24/01/2020

The US Food and Drug Administration (FDA) has established a Center of Excellence to improve the quality of compounded drugs, which are created by combining two or more drugs and are not FDA-approved.

Bevacizumab and teriparatide biosimilars launched in Japan Biosimilars/News | Posted 24/01/2020

Biosimilars for osteoporosis treatment teriparatide and for anticancer drug bevacizumab were launched in Japan in late 2019.

Real-life clinical effectiveness of Razumab in wet AMD Biosimilars/Research | Posted 24/01/2020

The multicentre, retrospective RE-ENACT 2 study evaluated the real-world effectiveness of ranibizumab biosimilar, Razumab, for the treatment of wet age-related macular degeneration (wet AMD). This...

US government department proposes rule to lower drug prices for its citizens Policies & Legislation | Posted 24/01/2020

The US Department of Health and Human Services (HHS) announced a string of changes in November 2019, including a proposal to lower drug prices for US citizens based on Trump’s ‘most favored nation’...